MAST - Magnesium for Sickle Cell Acute Crisis in Children

• Status: Completed
• Trial end date: 2013-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine if intravenous magnesium sulfate treatment is effective in reducing the length of stay and pain in children with sickle cell disease suffering an acute vaso-occlusive episode.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The Hospital for Sick Children
• Collaborator: The Physicians' Services Incorporated Foundation
• Treatments: Magnesium Sulfate

Criteria

Inclusion Criteria:

• Known sickle cell disease

• Previous painful crisis resulting in an Emergency Department(ED) visit

• Current visit with a chief complaint of pain

• Age 4 years - 18 years

• Staff ED decides to admit to the hospital

• Staff ED decides to start an intravenous line

Exclusion Criteria:

• Fever (>38.5C) during the 24 hours prior to visit at triage

• Patients transfused within 90 days of study entry

• Patients with known renal disease

• Patients with known heart block or myocardial damage

• Patients who take a magnesium-containing medication or calcium channel blocker on a regular basis

• Patients who received anesthetics, cardiac glycosides and neuromuscular blockers during the acute illness in the last 24 hours

• Patients or parents unable to communicate in English

• Known pregnancy

• Known allergy to Magnesium

• Admission to the ICU

• Enrolment to the study in the last 30 days